JPWO2019182901A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019182901A5 JPWO2019182901A5 JP2020542113A JP2020542113A JPWO2019182901A5 JP WO2019182901 A5 JPWO2019182901 A5 JP WO2019182901A5 JP 2020542113 A JP2020542113 A JP 2020542113A JP 2020542113 A JP2020542113 A JP 2020542113A JP WO2019182901 A5 JPWO2019182901 A5 JP WO2019182901A5
- Authority
- JP
- Japan
- Prior art keywords
- protein drug
- sample
- drug sample
- denatured
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
一実施形態では、サンプル濃度について確立されたアッセイ範囲は０．４ｍｇ／ｍｌ～０．６ｍｇ／ｍｌであり、分析されている約７μｇ／ｍｌ～１１μｇ／ｍｌの最終濃度に対応しており、この最終濃度がマイクロチップキャピラリー電気泳動システム上でＭＣＥ分析にかけられて、電気泳動図が作成される。この方法は、汚染物質または不純物に対応する、電気泳動図中のピークを特定することによって、完結する。
[本発明1001]
155～175ｍＭの2－ヨードアセトアミドと、
0．50～1．5％のドデシル硫酸リチウムと、
75～95ｍＭのリン酸ナトリウムと
を含み、
7未満のｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1002]
ｐＨが6である、本発明1001の水性緩衝液。
[本発明1003]
166ｍＭの2－ヨードアセトアミドと、0．81％のドデシル硫酸リチウムと、81ｍＭのリン酸ナトリウムとを含む、本発明1001または1002の水性緩衝液。
[本発明1004]
166ｍＭの2－ヨードアセトアミドと、
0．81％のドデシル硫酸リチウムと、
81ｍＭのリン酸ナトリウムと
から成り、
6．0のｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1005]
0．50～1．5％のドデシル硫酸リチウムと、
45～75ｍＭのリン酸ナトリウムと、
還元剤と
を含み、
8より大きいｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1006]
ｐＨが9である、本発明1005の水性緩衝液。
[本発明1007]
135～155ｍＭのジチオスレイトールを含む、本発明1005または1006の水性緩衝液。
[本発明1008]
0．69％のドデシル硫酸リチウムと、69ｍＭのリン酸ナトリウムと、142ｍＭのジチオスレイトールとを含む、本発明1005～1007のいずれかの水性緩衝液。
[本発明1009]
0．69％のドデシル硫酸リチウムと、
69ｍＭのリン酸ナトリウムと、
142ｍＭのジチオスレイトールと
から成り、
9．0のｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1010]
タンパク質薬物サンプル中の汚染物質または不純物を同定する方法であって、
前記タンパク質薬物サンプルを本発明1001～1004のいずれかの緩衝液に添加して、緩衝化されたタンパク質薬物サンプルを形成するステップと、
前記緩衝化されたタンパク質薬物サンプルを、65～85℃に5～15分間、加熱して、変性した緩衝化されたタンパク質薬物サンプルを形成するステップと、
前記変性した緩衝化されたタンパク質薬物サンプルに検出可能な標識を添加し、30～40℃で20～40分間、加熱して、変性した標識されたタンパク質薬物サンプルを形成するステップと、
前記変性した標識されたタンパク質薬物サンプルを希釈し、ＭＣＥにかけて、マイクロチップキャピラリー電気泳動システム上で、希釈されたタンパク質薬物サンプルを分離し、電気泳動図を作成するステップと、
汚染物質または不純物に対応する、前記電気泳動図におけるピークを同定するステップと
を含む、方法。
[本発明1011]
前記緩衝化されたタンパク質薬物サンプルを、70℃で10分間、加熱する、本発明1010の方法。
[本発明1012]
前記標識されたタンパク質薬物サンプルを、35℃で30分間、加熱する、本発明1010または1011の方法。
[本発明1013]
前記希釈されたタンパク質薬物サンプルが9ｍｇ／ｍｌである、本発明1010～1012のいずれかの方法。
[本発明1014]
タンパク質薬物サンプル中の汚染物質または不純物を同定する方法であって、
前記タンパク質サンプルを本発明1005～1009のいずれかの緩衝液に添加して、緩衝化されたタンパク質薬物サンプルを形成するステップと、
前記緩衝化されたタンパク質薬物サンプルを65～85℃に5～15分間、加熱して、変性したタンパク質薬物サンプルを形成するステップと、
前記変性したタンパク質薬物サンプルに、検出可能な標識を添加し、30～40℃で20～40分間、加熱して、変性した標識されたタンパク質薬物サンプルを形成するステップと、
前記変性した標識されたタンパク質薬物サンプルを希釈し、マイクロチップキャピラリー電気泳動システム上でＭＣＥ分析にかけて、電気泳動図を作成するステップと、
汚染物質または不純物に対応する、前記電気泳動図におけるピークを同定するステップと
を含む、方法。
[本発明1015]
前記緩衝化されたタンパク質薬物サンプルを、70℃で10分間、加熱する、本発明1014の方法。
[本発明1016]
前記サンプルを、35℃で30分間、加熱する、本発明1014または1015の方法。
[本発明1017]
前記希釈されたタンパク質薬物サンプルが9μｇ／ｍｌである、本発明1014～1016のいずれかの方法。
[本発明1018]
前記検出可能な標識がＤＹ－631 Ｎ－ヒドロキシスクシンイミジルエステルである、本発明1010～1017のいずれかの方法。
[本発明1019]
本発明1001～1009のいずれかの緩衝液と、前記緩衝液中での電気泳動のためにサンプルを調製するための書面による指示書とを含む、キット。
[本発明1020]
55～75ｍＭの2－ヨードアセトアミドと、
0．1～1．0％のドデシル硫酸リチウムと、
5～115ｍＭの塩化ナトリウムと、
5～85ｍＭのＨＥＰＥＳと
を含み、
9未満のｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1021]
66．4ｍＭの2－ヨードアセトアミドと、
0．32％のドデシル硫酸リチウムと、
48．6ｍＭのＮａＣｌと、
16．2ｍＭのＨＥＰＥＳと
を含み、
9未満のｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1022]
ｐＨが8である、本発明1020または1021の水性緩衝液。
[本発明1023]
0．05～0．75％のドデシル硫酸リチウムと、
5ｍＭ～115ｍＭのＮａＣｌと、
5ｍＭ～85ｍＭのＨＥＰＥＳと、
35～50ｍＭのジチオスレイトールと
を含み、
7より大きいｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1024]
0．28％のドデシル硫酸リチウムと、
41．5ｍＭのＮａＣｌと、
13．8ｍＭのＨＥＰＥＳと、
42．5ｍＭのジチオスレイトールと
を含み、
7より大きいｐＨを有する、
水性電気泳動サンプル緩衝液。
[本発明1025]
ｐＨが8である、本発明1023または1024の水性緩衝液。
In one embodiment, the established assay range for sample concentration is 0.4 mg / ml to 0.6 mg / ml, corresponding to the final concentration of about 7 μg / ml to 11 μg / ml being analyzed. The final concentration is subjected to MCE analysis on a microchip capillary electrophoresis system to produce an electrophoretogram. This method is completed by identifying peaks in the electrophoretogram that correspond to contaminants or impurities.
[Invention 1001]
With 155-175 mM 2-iodoacetamide,
With 0.50 to 1.5% lithium dodecyl sulfate,
With 75-95 mM sodium phosphate
Including
Has a pH of less than 7,
Aqueous electrophoresis sample buffer.
[Invention 1002]
The aqueous buffer of the present invention 1001 having a pH of 6.
[Invention 1003]
The 1001 or 1002 aqueous buffer of the invention comprising 166 mM 2-iodoacetamide, 0.81% lithium dodecyl sulfate and 81 mM sodium phosphate.
[Invention 1004]
With 166 mM 2-iodoacetamide,
With 0.81% lithium dodecyl sulfate,
With 81 mM sodium phosphate
Consists of
Has a pH of 6.0,
Aqueous electrophoresis sample buffer.
[Invention 1005]
With 0.50 to 1.5% lithium dodecyl sulfate,
45-75 mM sodium phosphate and
With a reducing agent
Including
Has a pH greater than 8,
Aqueous electrophoresis sample buffer.
[Invention 1006]
The aqueous buffer of the present invention 1005 having a pH of 9.
[Invention 1007]
Aqueous buffer of the present invention 1005 or 1006 containing 135-155 mM dithiothreitol.
[Invention 1008]
The aqueous buffer of any of 1005-1007 of the present invention comprising 0.69% lithium dodecyl sulfate, 69 mM sodium phosphate and 142 mM dithiothreitol.
[Invention 1009]
With 0.69% lithium dodecyl sulfate,
69 mM sodium phosphate and
With 142 mM dithiothreitol
Consists of
Has a pH of 9.0,
Aqueous electrophoresis sample buffer.
[Invention 1010]
A method for identifying contaminants or impurities in protein drug samples,
A step of adding the protein drug sample to any of the buffers of the present invention 1001 to 1004 to form a buffered protein drug sample.
The step of heating the buffered protein drug sample to 65-85 ° C. for 5-15 minutes to form a denatured buffered protein drug sample.
A step of adding a detectable label to the denatured buffered protein drug sample and heating at 30-40 ° C. for 20-40 minutes to form a denatured labeled protein drug sample.
A step of diluting the denatured labeled protein drug sample, subjecting it to MCE, separating the diluted protein drug sample on a microchip capillary electrophoresis system, and creating an electrophoretogram.
Steps to identify peaks in the electrophoretogram corresponding to contaminants or impurities
Including, how.
[Invention 1011]
The method of the invention 1010, wherein the buffered protein drug sample is heated at 70 ° C. for 10 minutes.
[Invention 1012]
The method of the invention 1010 or 1011, wherein the labeled protein drug sample is heated at 35 ° C. for 30 minutes.
[Invention 1013]
The method of any of 1010-1012 of the present invention, wherein the diluted protein drug sample is 9 mg / ml.
[Invention 1014]
A method for identifying contaminants or impurities in protein drug samples,
A step of adding the protein sample to any of the buffers of the present invention 1005 to 1009 to form a buffered protein drug sample.
A step of heating the buffered protein drug sample to 65-85 ° C. for 5-15 minutes to form a denatured protein drug sample.
A step of adding a detectable label to the denatured protein drug sample and heating at 30-40 ° C. for 20-40 minutes to form a denatured labeled protein drug sample.
A step of diluting the denatured labeled protein drug sample and subjecting it to MCE analysis on a microchip capillary electrophoresis system to create an electrophoretogram.
Steps to identify peaks in the electrophoretogram corresponding to contaminants or impurities
Including, how.
[Invention 1015]
The method of the invention 1014, wherein the buffered protein drug sample is heated at 70 ° C. for 10 minutes.
[Invention 1016]
The method of the invention 1014 or 1015, wherein the sample is heated at 35 ° C. for 30 minutes.
[Invention 1017]
The method of any of 1014-1016 of the present invention, wherein the diluted protein drug sample is 9 μg / ml.
[Invention 1018]
The method of any of 1010-1017 of the present invention, wherein the detectable label is DY-631 N-hydroxysuccinimidyl ester.
[Invention 1019]
A kit comprising any of the buffers 1001-1009 of the present invention and written instructions for preparing a sample for electrophoresis in said buffer.
[Invention 1020]
55-75 mM 2-iodoacetamide,
With 0.1-1.0% lithium dodecyl sulfate,
5 to 115 mM sodium chloride and
With 5 to 85 mM HEPES
Including
Has a pH of less than 9,
Aqueous electrophoresis sample buffer.
[Invention 1021]
66.4 mM 2-iodoacetamide and
With 0.32% lithium dodecyl sulfate,
48.6 mM NaCl and
With 16.2 mM HEPES
Including
Has a pH of less than 9,
Aqueous electrophoresis sample buffer.
[Invention 1022]
Aqueous buffer of the invention 1020 or 1021 having a pH of 8.
[Invention 1023]
With 0.05 to 0.75% lithium dodecyl sulfate,
5 mM to 115 mM NaCl and
With 5 mM to 85 mM HEPES,
With 35-50 mM dithiothreitol
Including
Has a pH greater than 7,
Aqueous electrophoresis sample buffer.
[Invention 1024]
With 0.28% lithium dodecyl sulfate,
41.5 mM NaCl and
13.8 mM HEPES and
With 42.5 mM dithiothreitol
Including
Has a pH greater than 7,
Aqueous electrophoresis sample buffer.
[Invention 1025]
Aqueous buffer of the present invention 1023 or 1024 having a pH of 8.
Claims (17)
０．５０～１．５％のドデシル硫酸リチウムと、
７５～９５ｍＭのリン酸ナトリウムと
を含み、
７未満のｐＨを有する、
水性電気泳動サンプル緩衝液。 With 155 to 175 mM 2-iodoacetamide,
With 0.50 to 1.5% lithium dodecyl sulfate,
Contains 75-95 mM sodium phosphate and
Has a pH of less than 7,
Aqueous electrophoresis sample buffer.
０．８１％のドデシル硫酸リチウムと、
８１ｍＭのリン酸ナトリウムと
から成り、
６．０のｐＨを有する、
水性電気泳動サンプル緩衝液。 With 166 mM 2-iodoacetamide,
With 0.81% lithium dodecyl sulfate,
Consists of 81 mM sodium phosphate
Has a pH of 6.0,
Aqueous electrophoresis sample buffer.
前記タンパク質薬物サンプルを、１５５～１７５ｍＭの２－ヨードアセトアミドと０．５０～１．５％のドデシル硫酸リチウムと７５～９５ｍＭのリン酸ナトリウムを含み、７未満のｐＨを有する、水性電気泳動サンプル緩衝液に添加して、緩衝化されたタンパク質薬物サンプルを形成するステップと、
前記緩衝化されたタンパク質薬物サンプルを、６５～８５℃に５～１５分間、加熱して、変性した緩衝化されたタンパク質薬物サンプルを形成するステップと、
前記変性した緩衝化されたタンパク質薬物サンプルに検出可能な標識を添加し、３０～４０℃で２０～４０分間、加熱して、変性した標識されたタンパク質薬物サンプルを形成するステップと、
前記変性した標識されたタンパク質薬物サンプルを希釈し、マイクロチップキャピラリー電気泳動にかけて、マイクロチップキャピラリー電気泳動システム上で、希釈された変性した標識されたタンパク質薬物サンプルを分離し、電気泳動図を作成するステップと、
汚染物質または不純物に対応する、前記電気泳動図におけるピークを同定するステップと
を含む、方法。 A method for identifying contaminants or impurities in protein drug samples,
The protein drug sample contains an aqueous electrophoresis sample buffer containing 155 to 175 mM 2-iodoacetamide, 0.50 to 1.5% lithium dodecyl sulfate and 75 to 95 mM sodium phosphate and having a pH of less than 7. Steps to add to the solution to form a buffered protein drug sample,
The step of heating the buffered protein drug sample to 65-85 ° C. for 5-15 minutes to form a denatured buffered protein drug sample.
A step of adding a detectable label to the denatured buffered protein drug sample and heating at 30-40 ° C. for 20-40 minutes to form a denatured labeled protein drug sample.
The denatured labeled protein drug sample is diluted and subjected to microchip capillary electrophoresis to separate the diluted denatured labeled protein drug sample on a microchip capillary electrophoresis system and create an electrophoretogram. Steps and
A method comprising the step of identifying a peak in the electrophoretogram corresponding to a contaminant or impurity.
前記タンパク質サンプルを、０．５０～１．５％のドデシル硫酸リチウムと４５～７５ｍＭのリン酸ナトリウムと還元剤とを含み、８より大きいｐＨを有する、水性電気泳動サンプル緩衝液に添加して、緩衝化されたタンパク質薬物サンプルを形成するステップと、
前記緩衝化されたタンパク質薬物サンプルを６５～８５℃に５～１５分間、加熱して、変性したタンパク質薬物サンプルを形成するステップと、
前記変性したタンパク質薬物サンプルに、検出可能な標識を添加し、３０～４０℃で２０～４０分間、加熱して、変性した標識されたタンパク質薬物サンプルを形成するステップと、
前記変性した標識されたタンパク質薬物サンプルを希釈し、マイクロチップキャピラリー電気泳動システム上でマイクロチップキャピラリー電気泳動分析にかけて、電気泳動図を作成するステップと、
汚染物質または不純物に対応する、前記電気泳動図におけるピークを同定するステップと
を含む、方法。 A method for identifying contaminants or impurities in protein drug samples,
The protein sample was added to an aqueous electrophoresis sample buffer containing 0.50 to 1.5% lithium dodecyl sulfate, 45 to 75 mM sodium phosphate and a reducing agent and having a pH greater than 8 . Steps to form a buffered protein drug sample,
A step of heating the buffered protein drug sample to 65-85 ° C. for 5-15 minutes to form a denatured protein drug sample.
A step of adding a detectable label to the denatured protein drug sample and heating at 30-40 ° C. for 20-40 minutes to form a denatured labeled protein drug sample.
A step of diluting the denatured labeled protein drug sample and subjecting it to microchip capillary electrophoresis analysis on a microchip capillary electrophoresis system to create an electrophoretic diagram.
A method comprising the step of identifying a peak in the electrophoretogram corresponding to a contaminant or impurity.
０．１～１．０％のドデシル硫酸リチウムと、
５～１１５ｍＭの塩化ナトリウムと、
５～８５ｍＭのＨＥＰＥＳと
を含み、
９未満のｐＨを有する、
水性電気泳動サンプル緩衝液。 55-75 mM 2-iodoacetamide and
With 0.1-1.0% lithium dodecyl sulfate,
5 to 115 mM sodium chloride and
Including 5 to 85 mM HEPES
Has a pH of less than 9,
Aqueous electrophoresis sample buffer.
０．３２％のドデシル硫酸リチウムと、
４８．６ｍＭのＮａＣｌと、
１６．２ｍＭのＨＥＰＥＳと
を含み、
９未満のｐＨを有する、
水性電気泳動サンプル緩衝液。 66.4 mM 2-iodoacetamide and
With 0.32% lithium dodecyl sulfate,
48.6 mM NaCl and
Including 16.2 mM HEPES
Has a pH of less than 9,
Aqueous electrophoresis sample buffer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023070686A JP7486637B2 (en) | 2018-03-19 | 2023-04-24 | Microchip Capillary Electrophoresis Assays and Reagents |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644933P | 2018-03-19 | 2018-03-19 | |
| US62/644,933 | 2018-03-19 | ||
| PCT/US2019/022525 WO2019182901A1 (en) | 2018-03-19 | 2019-03-15 | Microchip capillary electrophoresis assays and reagents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023070686A Division JP7486637B2 (en) | 2018-03-19 | 2023-04-24 | Microchip Capillary Electrophoresis Assays and Reagents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516334A JP2021516334A (en) | 2021-07-01 |
| JPWO2019182901A5 true JPWO2019182901A5 (en) | 2022-03-18 |
| JP7315565B2 JP7315565B2 (en) | 2023-07-26 |
Family
ID=65952203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542113A Active JP7315565B2 (en) | 2018-03-19 | 2019-03-15 | Microchip capillary electrophoresis assays and reagents |
| JP2023070686A Active JP7486637B2 (en) | 2018-03-19 | 2023-04-24 | Microchip Capillary Electrophoresis Assays and Reagents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023070686A Active JP7486637B2 (en) | 2018-03-19 | 2023-04-24 | Microchip Capillary Electrophoresis Assays and Reagents |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11054389B2 (en) |
| EP (2) | EP4317959A3 (en) |
| JP (2) | JP7315565B2 (en) |
| KR (2) | KR102503356B1 (en) |
| CN (1) | CN111868085A (en) |
| AR (1) | AR117402A1 (en) |
| AU (1) | AU2019239633A1 (en) |
| BR (1) | BR112020015291B1 (en) |
| CA (1) | CA3089655A1 (en) |
| DK (1) | DK3768709T3 (en) |
| EA (1) | EA202092203A1 (en) |
| FI (1) | FI3768709T3 (en) |
| IL (2) | IL307577A (en) |
| MX (1) | MX2020009696A (en) |
| SG (1) | SG11202007011YA (en) |
| TW (2) | TWI779177B (en) |
| WO (1) | WO2019182901A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3089655A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| JP7342279B2 (en) * | 2020-01-21 | 2023-09-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Deglycosylation method for electrophoresis of glycosylated proteins |
| TW202233827A (en) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | Methods of improving protein titer in cell culture |
| CN113189184B (en) * | 2021-04-28 | 2022-09-09 | 浙江大学 | Capillary gel electrophoresis sample buffer solution containing cysteine |
| EP4348234A1 (en) * | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818745B1 (en) * | 1998-05-18 | 2004-11-16 | University College London | Polypeptide hormone phosphatonin |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1506399A2 (en) | 2001-05-21 | 2005-02-16 | Aclara BioSciences, Inc. | Methods and compositions for analyzing proteins |
| JP2003114216A (en) * | 2001-10-05 | 2003-04-18 | Advance Co Ltd | Electrophoretic device |
| PL375045A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Gasp1: a follistatin domain containing protein |
| US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| DE10258150A1 (en) | 2002-12-10 | 2004-07-08 | Dyomics Gmbh | Hydrophilic markers based on benzopyrylo-polymethines |
| AU2003903317A0 (en) * | 2003-06-27 | 2003-07-10 | Proteome Systems Intellectual Property Pty Ltd | Method of isolating a protein |
| EP2306192B1 (en) * | 2003-12-05 | 2015-10-14 | The Cleveland Clinic Foundation | Risk Markers For Cardiovascular Disease |
| US7378396B2 (en) | 2004-08-11 | 2008-05-27 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
| ES2398076T3 (en) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies against the human IL-6 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2614832T3 (en) * | 2007-02-12 | 2017-01-31 | A1M Pharma Ab | Diagnosis and treatment of preeclampsia |
| EP2158328B1 (en) * | 2007-05-18 | 2014-01-01 | Life Technologies Corporation | Rapid protein labeling and analysis |
| PL2178916T3 (en) | 2007-07-31 | 2015-08-31 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| NZ592436A (en) * | 2008-11-06 | 2012-10-26 | Glenmark Pharmaceuticals Sa | Treatment with anti-alpha2 integrin antibodies |
| JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
| EP2975051B1 (en) | 2009-06-26 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| US8778685B2 (en) * | 2009-08-25 | 2014-07-15 | Life Technologies Corporation | Quantitative fluorescent protein standards |
| JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
| JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
| JOP20190250A1 (en) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | Stabilized formulations containing anti-ngf antibodies |
| AR083044A1 (en) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
| CN106267189B (en) | 2010-10-06 | 2021-02-26 | 瑞泽恩制药公司 | Stable formulations containing anti-interleukin-4 receptor (IL-4R) antibodies |
| JO3756B1 (en) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to the glucagon receptor |
| AR087329A1 (en) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | HUMAN ANTIBODIES AGAINST PROTEIN 3 OF HUMAN ANGIOPOIETIN TYPE |
| LT2780368T (en) | 2011-11-14 | 2018-03-12 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
| EP2807190B1 (en) | 2012-01-23 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
| JO3820B1 (en) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | Human antibodies to fel d1 and methods of use thereof |
| TW201843172A (en) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
| EA028244B1 (en) | 2012-08-13 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS |
| JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
| WO2014055936A1 (en) * | 2012-10-04 | 2014-04-10 | Integenx Inc. | Preservation of biological materials in non-aqueous fluid media |
| US10357538B2 (en) * | 2012-12-24 | 2019-07-23 | Northern Sydney Local Health District | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
| JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
| EP2948177A1 (en) | 2013-01-22 | 2015-12-02 | AbbVie Inc. | Methods for optimizing domain stability of binding proteins |
| JO3532B1 (en) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
| TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
| US9637535B2 (en) | 2013-03-15 | 2017-05-02 | Regeneron Pharmaceuticals, Inc. | IL-33 antagonists and uses thereof |
| TWI641620B (en) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | Anti-prlr antibodies and uses thereof |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| JP6632984B2 (en) | 2014-03-11 | 2020-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Anti-EGFRvIII antibodies and uses thereof |
| TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
| EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
| EA201790377A1 (en) | 2014-09-16 | 2017-08-31 | Регенерон Фармасьютикалз, Инк. | ANTIBODIES TO GLUCAGON AND THEIR APPLICATIONS |
| TWI710573B (en) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | Human antibodies to ebola virus glycoprotein |
| CA3089655A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
-
2019
- 2019-03-15 CA CA3089655A patent/CA3089655A1/en active Pending
- 2019-03-15 EP EP23210273.1A patent/EP4317959A3/en active Pending
- 2019-03-15 BR BR112020015291-9A patent/BR112020015291B1/en active IP Right Grant
- 2019-03-15 TW TW108108839A patent/TWI779177B/en active
- 2019-03-15 KR KR1020207026013A patent/KR102503356B1/en active IP Right Grant
- 2019-03-15 TW TW111141525A patent/TW202323813A/en unknown
- 2019-03-15 KR KR1020237006012A patent/KR20230031987A/en active Application Filing
- 2019-03-15 WO PCT/US2019/022525 patent/WO2019182901A1/en active Application Filing
- 2019-03-15 EA EA202092203A patent/EA202092203A1/en unknown
- 2019-03-15 US US16/355,050 patent/US11054389B2/en active Active
- 2019-03-15 JP JP2020542113A patent/JP7315565B2/en active Active
- 2019-03-15 CN CN201980020003.2A patent/CN111868085A/en active Pending
- 2019-03-15 AU AU2019239633A patent/AU2019239633A1/en active Pending
- 2019-03-15 IL IL307577A patent/IL307577A/en unknown
- 2019-03-15 IL IL277264A patent/IL277264B2/en unknown
- 2019-03-15 FI FIEP19714055.1T patent/FI3768709T3/en active
- 2019-03-15 MX MX2020009696A patent/MX2020009696A/en unknown
- 2019-03-15 EP EP19714055.1A patent/EP3768709B1/en active Active
- 2019-03-15 DK DK19714055.1T patent/DK3768709T3/en active
- 2019-03-15 SG SG11202007011YA patent/SG11202007011YA/en unknown
- 2019-03-19 AR ARP190100686A patent/AR117402A1/en unknown
-
2023
- 2023-04-24 JP JP2023070686A patent/JP7486637B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277264B1 (en) | Microchip capillary electrophoresis assays and reagents | |
| John et al. | Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for detection and identification of albumin phosphylation by organophosphorus pesticides and G-and V-type nerve agents | |
| JPWO2019182901A5 (en) | ||
| BRPI0501751A (en) | capillary electrophoresis process, electrophoresis separation process, electrophoretic separation process, capillary electrophoresis composition and assay kit | |
| US10625242B2 (en) | Substrates and methods for collection, stabilization and elution of biomolecules | |
| Kleiman et al. | Reconstitution of chromatin: The sequential binding of histones to DNA in the presence of salt and urea | |
| RU2006130740A (en) | METHOD FOR DETERMINING DNA FRAGMENT IN ANIMAL Spermatozoa | |
| Righetti et al. | Plucking, pillaging and plundering proteomes with combinatorial peptide ligand libraries | |
| CN108796041A (en) | A kind of amplification of signal system and its detection method based on bioluminescence resonance energy transfer | |
| DE60325976D1 (en) | ENHANCEMENT OF PLASMA PROTEINS | |
| Li et al. | Analysis of silver-associated proteins in pathogen via combination of native SDS-PAGE, fluorescent staining, and inductively coupled plasma mass spectrometry | |
| US20050100878A1 (en) | Method for the quantitative determination of one or more compounds | |
| Furlong et al. | Expression of human proacrosin in Escherichia coli and binding to zona pellucida | |
| Lin et al. | A comprehensive evaluation of imidazole‐zinc reverse stain for current proteomic researches | |
| Santhanam et al. | Selective fluorescent labeling of S-nitrosothiols (S-FLOS): a novel method for studying S-nitrosation | |
| Carraro et al. | A new two-step precipitation method removes free-SDS and thiol reagents from diluted solutions, and then allows recovery and quantitation of proteins | |
| Castellanos-Serra et al. | Negative detection of biomolecules separated in polyacrylamide electrophoresis gels | |
| BR112023024984A2 (en) | AQUEOUS ELECTROPHORESIS SAMPLE BUFFER, METHOD FOR IDENTIFYING CONTAMINANTS OR IMPURITIES IN A PROTEIN DRUG SAMPLE, AND, KIT | |
| BR0203700A (en) | Capillary electrophoresis process in alkaline ph free solution | |
| Shimazaki et al. | Retaining activity of enzymes after capture and extraction within a single-drop of biological fluid using immunoaffinity membranes | |
| Bajaj et al. | Method of extraction and proteome profiling of mycobacteria using liquid chromatography-high resolution mass spectrometry | |
| JP6742235B2 (en) | Protein detection method using mass spectrometry | |
| Antharavally et al. | A Versatile High-Recovery Method For Removing Detergents From Low-Concentration Protein or Peptide Samples For Mass Spectrometry Sample Preparation And Analysis | |
| US20150175998A1 (en) | Methods and Kits to Create Protein Substrate˜HECT-Ubiquitin Ligase Pairs | |
| Devraj et al. | Improved membrane protein solubilization and clean-up for optimum two-dimensional electrophoresis utilizing GLUT-1 as a classic integral membrane protein |